RGNX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [3]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [2]. - The complaint alleges that REGENXBIO and its executives made false and/or misleading statements and failed to disclose material adverse facts concerning the RGX-111 trial [3]. Group 2: Clinical Hold and Stock Impact - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy following a case of neoplasm in a trial participant [4]. - The FDA also placed a clinical hold on RGX-121 for similar reasons, leading to a stock price drop of $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [4]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in REGENXBIO to contact them directly to discuss their legal options [1]. - The firm is also seeking information regarding REGENXBIO's conduct from whistleblowers, former employees, and shareholders [6].